There are many advantages of administrating conventional combinational chemotherapy via oral route over intravenous route in cancer patients and that is also true for lung cancers. This eliminates the possibility of frequent hospital stay, reduces the side effects like fatigue, nausea, vomiting which ultimately enhances the quality of life.
It is challenging to prepare the formulation for ‘Oral chemotherapy’ since oral route is having various issues like poor solubility, stability and permeability and a little chance to get into the blood system and thus reach the tumor site. Dr Mayur Patel and Dr Bhoomika Patel from Institute of Pharmacy, Nirma University took this challenge and prepared a novel formulation of Docetaxel and Cisplatin for oral delivery of the anticancer agent for the treatment of lung cancer using nanotechnology. This research project entitled ‘Formulation Development and Evaluation of Nanoparticulate Systems for Targeted Delivery of Anticancer Agent’ is funded by the Nirma University.
The innovative nano-formulation prepared was tested both in vitro (lung cancer cell line) and in vivo in animals. The studies have shown that the novel system delivers the drug on target site, i.e., tumors targeting. The formulation reduced certain markers that are associated with tumor pathogenesis and also demonstrated significant regression of tumors. As compared to the marketed formulations, the developed novel formulation was associated with minimal toxicity and was found safe for animals.
This ‘Convenient Painless Oral Chemotherapy’ offers several benefits like high patient compliance and cheaper production. The major advantage is that the patient can take this from home and hence it is named as ‘Therapy at Home’. Oral Chemotherapy will be a boon for the patients who cannot withstand the harsh medical treatment. It can maintain a sustained moderate plasma concentration of the drug to achieve a prolonged exposure of cancerous cells to the drug. It also avoids plasma concentrations of the drug to exceed the mean therapeutic concentration, resulting in better efficacy and fewer side effects than the current intermittent parenteral chemotherapy. The novel approach may prove to be a beneficial step to facilitate the patients to maintain their quality of life and recover quickly due to higher comfort and compliance.